Toxicology – Second-Generation (“Nonsedating”) Antihistamines

Core Concept

The older term “nonsedating antihistamines” generally refers to second-generation H1 antihistamines.

Modern examples include:

• Cetirizine
• Levocetirizine
• Loratadine
• Desloratadine
• Fexofenadine
• Acrivastine in some regions

These agents penetrate the CNS less readily than first-generation antihistamines and therefore usually produce less sedation and fewer antimuscarinic effects.

Most isolated overdoses are relatively mild.

The major cardiac toxicity emphasized in older literature—marked QT prolongation and torsades—was primarily associated with astemizole and terfenadine, drugs that have been withdrawn or are no longer routinely marketed in many countries.

Historical Agents – Astemizole and Terfenadine

Astemizole and terfenadine are important historically because they demonstrated that an apparently “nonsedating” antihistamine could still cause severe cardiac toxicity.

Both could block cardiac repolarizing potassium currents and produce:

QT prolongation → early afterdepolarizations → torsades de pointes → ventricular fibrillation/cardiac arrest

Risk became especially important when their metabolism was inhibited by interacting medications.

Modern second-generation antihistamines generally have a much more favorable cardiac safety profile.

Mechanism

Second-generation antihistamines primarily antagonize peripheral H1 receptors.

H1 blockade reduces allergic manifestations such as:

• Pruritus
• Sneezing
• Rhinorrhea
• Urticaria

Their limited CNS penetration accounts for less sedation compared with agents such as diphenhydramine.

However, “nonsedating” is not absolute.

Cetirizine

Cetirizine is relatively more likely than some other second-generation agents to cause:

• Drowsiness
• Fatigue
• Dizziness

Overdose usually produces mild CNS effects rather than severe cardiotoxicity.

Loratadine

Loratadine and its active metabolite desloratadine generally have limited CNS penetration.

Overdose may produce:

• Somnolence
• Headache
• Tachycardia

Serious isolated cardiotoxicity is uncommon.

Fexofenadine

Fexofenadine is the active metabolite related to the older drug terfenadine.

Unlike terfenadine, it has substantially less potential for clinically important cardiac potassium-channel blockade.

This explains why:

Terfenadine → important historical torsades risk

whereas:

Fexofenadine → much lower cardiac risk

Most isolated fexofenadine overdoses are mild.

Acrivastine

Acrivastine can produce:

• Drowsiness
• Dizziness
• Headache
• GI symptoms

Some preparations contain pseudoephedrine.

This distinction is crucial because toxicity from a combination product may reflect the sympathomimetic component rather than the antihistamine.

Combination Products

Always determine whether the preparation contains another active ingredient.

Examples include antihistamine products combined with:

• Pseudoephedrine
• Other decongestants
• Analgesics in some formulations

Pseudoephedrine can produce:

• Agitation
• Tremor
• Tachycardia
• Hypertension
• Insomnia

Therefore, a markedly hyperadrenergic presentation after an “antihistamine” ingestion should prompt inspection of the actual formulation.

Toxic Dose

There is no single useful toxic-dose threshold covering all second-generation antihistamines.

For currently used agents, isolated accidental overdose generally has a relatively wide safety margin.

Risk assessment should consider:

• Exact agent
• Amount
• Patient age/size
• Symptoms
• Coingestants
• Combination-product ingredients
• Renal/hepatic impairment where relevant

Historical astemizole and terfenadine toxicity should not be extrapolated directly to modern agents.

Clinical Features

Most uncomplicated overdoses produce only:

• Drowsiness
• Dizziness
• Headache
• Nausea
• Dry mouth
• Mild tachycardia

Large exposures may occasionally produce:

• Agitation
• Tremor
• Ataxia
• Significant somnolence

Severe neurologic or cardiovascular toxicity should prompt consideration of another agent or coingestant.

Sedation

The label “nonsedating” is misleading if interpreted literally.

Second-generation antihistamines cause less CNS H1 blockade, but some sedation remains possible.

Cetirizine is particularly associated with somnolence compared with fexofenadine.

Antimuscarinic Effects

Modern second-generation antihistamines generally have much weaker antimuscarinic effects than first-generation agents.

Prominent findings such as:

• Severe delirium
• Marked mydriasis
• Very dry skin
• Urinary retention
• Ileus
• Major QRS widening

should raise concern for:

• Diphenhydramine
• Doxylamine
• Another first-generation antihistamine
• TCA
• Another antimuscarinic/sodium-channel blocker
• Mixed ingestion

Cardiovascular Effects

With current second-generation agents, cardiovascular effects are usually limited.

Possible findings include:

• Mild tachycardia
• Occasionally palpitations

Major ventricular dysrhythmia is uncommon in isolated overdose of modern agents.

Astemizole Cardiotoxicity

Historical astemizole toxicity could produce:

• QT prolongation
• Syncope
• Torsades de pointes
• Ventricular dysrhythmia
• Hypotension
• Cardiovascular collapse

Its prolonged pharmacokinetics also allowed delayed toxicity.

These historical features explain the prolonged monitoring recommendations in older texts but should not automatically be applied to cetirizine, loratadine, or fexofenadine.

Drug Interactions – Historical Lesson

Astemizole and terfenadine depended heavily on hepatic metabolism.

Inhibition of their metabolism could increase parent-drug concentrations and markedly increase QT-related toxicity.

Historically important interacting drugs included some:

• Azole antifungals
• Macrolide antibiotics
• CYP inhibitors

This interaction was one of the major reasons these drugs disappeared from routine clinical use.

QT Prolongation – Modern Approach

If clinically important QT prolongation occurs:

• Review the exact antihistamine
• Look for coingestants
• Check potassium
• Check magnesium
• Consider calcium when appropriate
• Review other QT-prolonging medications
• Consider congenital/acquired long-QT conditions

Marked QT prolongation should not automatically be attributed to a modern second-generation antihistamine.

Torsades de Pointes

If torsades develops:

• Stop QT-prolonging drugs
• Correct hypokalemia
• Correct hypomagnesemia
• Give IV magnesium
• Treat unstable ventricular dysrhythmia electrically

Recurrent pause-dependent torsades associated with bradycardia may require heart-rate acceleration, including selected use of overdrive pacing.

Avoid adding medications that further prolong the QT interval.

Neurologic Effects

Large exposures may cause:

• Somnolence
• Dizziness
• Headache
• Tremor
• Agitation
• Ataxia

Seizures are unusual with modern second-generation antihistamines.

If seizures occur, evaluate for:

• Large/mixed ingestion
• First-generation antihistamine
• Sympathomimetic combination product
• Other proconvulsant
• Metabolic or neurologic cause

Seizure Treatment

Benzodiazepines are first-line therapy for toxicant-induced seizures.

Persistent seizures may require:

• Additional benzodiazepines
• Phenobarbital
• Appropriate anesthetic status-epilepticus treatment

The older recommendation to routinely progress to phenytoin is outdated; phenytoin is generally not preferred for toxicologic seizures.

Hepatic Effects

Rare liver injury has been reported with antihistamines, but it is not a defining manifestation of acute second-generation antihistamine overdose.

Liver testing should therefore be driven by:

• Symptoms
• Prolonged exposure
• Coingestants
• Other clinical concerns

rather than performed routinely after every uncomplicated exposure.

Diagnosis

Diagnosis is usually clinical.

Determine:

• Exact product
• Immediate vs combination formulation
• Amount
• Time
• Symptoms
• Coingestants
• Relevant medical conditions

Identifying the exact product is particularly important because a “non-drowsy allergy tablet” may contain a decongestant.

ECG

An ECG is reasonable when there is:

• Syncope
• Palpitations
• Significant tachycardia
• Intentional or substantial overdose
• Suspected QT-active drug
• Electrolyte abnormality
• Concerning coingestant
• Cardiovascular symptoms

Routine prolonged ECG monitoring is generally unnecessary after every small asymptomatic exposure to a modern second-generation antihistamine.

Laboratory Evaluation

Small uncomplicated exposures may require no laboratory testing.

When clinically indicated, consider:

• Glucose
• Electrolytes
• Potassium
• Magnesium
• Creatinine

Additional testing depends on:

• Intentional overdose
• Coingestants
• ECG abnormalities
• Altered mental status

Drug concentrations are not routinely useful.

Occult Coingestion

Intentional overdose should prompt evaluation for clinically important coingestants.

Acetaminophen testing is often relevant because early toxicity can be asymptomatic.

Other testing should be directed by history and clinical findings rather than performed mechanically.

Initial Management

Management is predominantly supportive:

Airway/breathing → mental status → circulation → identify exact formulation → ECG when indicated → treat complications

Most isolated modern second-generation antihistamine overdoses do not require aggressive intervention.

GI Decontamination

Do not induce vomiting.

Routine gastric lavage is obsolete.

Activated charcoal may occasionally be considered after a substantial recent ingestion when:

• The substance is adsorbable
• The airway is safe
• Aspiration risk is low
• Expected benefit justifies treatment

Routine decontamination is unnecessary after many minor accidental exposures.

Hypotension

Significant hypotension is unusual after isolated modern second-generation antihistamine overdose.

If it occurs, evaluate for:

• Coingestants
• Dysrhythmia
• Dehydration
• Another medical cause

Treatment may include appropriate isotonic crystalloid and, for persistent vasodilatory shock, a vasopressor such as norepinephrine.

Trendelenburg positioning and routine dopamine-first therapy are outdated.

Extracorporeal Elimination

Hemodialysis and hemoperfusion have no routine role in second-generation antihistamine poisoning.

Supportive care is generally sufficient.

Monitoring

Monitoring should be proportional to the exposure.

Mild modern-agent exposure

Monitor:

• Mental status
• Vital signs
• Development of unexpected symptoms

Significant or symptomatic exposure

Consider:

• ECG
• Cardiac rhythm
• Electrolytes
• Neurologic status

QT prolongation

Continue ECG monitoring until clinically important repolarization abnormalities and associated risk factors have resolved.

Observation

The historical blanket recommendation of:

• 6 hours for all uncomplicated exposures
• 24 hours for hospitalized patients

is too rigid.

Observation should depend on:

• Exact agent
• Amount
• Symptoms
• ECG
• Combination ingredients
• Coingestants
• Clinical trajectory

Historical prolonged monitoring for astemizole should not be automatically transferred to currently used agents.

Admission

Hospital admission may be appropriate for:

• Significant altered mental status
• Seizure
• Syncope with concerning ECG findings
• Important QT prolongation
• Ventricular dysrhythmia
• Persistent hypotension
• Significant coingestion

ICU care is appropriate for torsades, cardiovascular collapse, or other severe toxicity.

Pregnancy and Breastfeeding

The historical FDA pregnancy letter categories are obsolete.

Cetirizine and loratadine have substantial clinical experience in pregnancy, but medication decisions should consider:

• Specific drug
• Dose
• Gestational stage
• Clinical indication

The old blanket statement that cetirizine or loratadine should generally be avoided during breastfeeding is also too broad.

Drug transfer into milk and infant effects vary by agent, and current lactation-specific guidance should be used.

Safeguarding

Rigid historical age thresholds for neglect, abuse, or intentional poisoning are inappropriate.

Pediatric exposures should instead be assessed according to:

• Developmental capability
• Medication accessibility
• Exposure circumstances
• Consistency of history
• Recurrent unexplained exposures
• Broader safeguarding concerns

Intentional self-poisoning requires appropriate safety assessment after medical stabilization.

Prognosis

Most isolated overdoses involving currently used second-generation antihistamines have a favorable outcome.

Severe toxicity should prompt particular attention to:

• Combination products
• Coingestants
• Electrolyte disturbances
• Unexpected first-generation antihistamine exposure
• Historical QT-active agents

Important Modernization of the Older Source

• “Nonsedating” is better described as second-generation H1 antihistamines; sedation can still occur.
• Astemizole is largely historical and its severe QT toxicity should not define the entire modern class.
• Terfenadine is likewise largely historical because of serious interaction-mediated cardiotoxicity.
• Modern agents such as cetirizine, loratadine, and fexofenadine generally have a much wider cardiovascular safety margin.
• Fexofenadine lacks the major torsadogenic liability of its historical precursor terfenadine.
• Cetirizine can still cause clinically noticeable drowsiness.
• Combination products containing pseudoephedrine can produce a sympathomimetic syndrome.
• Severe antimuscarinic delirium or QRS widening is atypical for modern second-generation agents and should prompt a search for another toxicant.
• Routine prolonged cardiac monitoring is unnecessary after every minor modern-agent exposure.
• Phenytoin is generally not preferred for toxicologic seizures.
• Ipecac and routine gastric lavage are obsolete.
• Trendelenburg and dopamine-first shock treatment are outdated.
• Observation should be agent-, symptom-, ECG-, and coingestant-specific.
• There is no specific antidote.

Key Points

• Second-generation antihistamines usually cause mild toxicity in isolated overdose.
• Common effects are drowsiness, dizziness, headache, nausea, and mild tachycardia.
• Cetirizine is relatively more sedating; fexofenadine has very little CNS effect.
• Astemizole and terfenadine are historical exceptions with major QT/torsades toxicity.
• Marked QT prolongation with a modern agent should prompt evaluation for electrolytes, interactions, and coingestants.
• IV magnesium + electrolyte correction are central if torsades occurs.
• Benzodiazepines are first-line for the unusual toxicologic seizure.
• Always check whether the product also contains pseudoephedrine or another active drug.
• Management is primarily supportive.